Pandemic Agreement Timetable Leaves Little Room for December Adoption

(So Big mRNA wants to hold a vote for the Plandemic Treaty by Dec.?  Not out of the woods yet folks)

'“We must always keep the urgency of this generational agreement at the forefront because, as the current outbreak of H5N1 reminds us, the next pandemic may be around the corner,” added Tedros.' Health Watch

• Cow Sneezes the Next Bat Soup?
• Cooking Up Big Orders of H5N1 Jabs... 'just in case'

from Health Watch

As delegates at this week’s Intergovernmental Negotiating Body (INB) worked to nail down a day-by-day agenda for negotiating a pandemic agreement for the next few months, it appears increasingly unlikely that the talks will be concluded by year-end. 

The detailed work plan – an indication that the Bureau has heard criticism that it has given member states too little notice in the past – underscores that there is so much to do in so little time.

As US Ambassador Pamela Hamamoto noted on the first day of the meeting, the work proposal for the next INB meeting in September “assumes we can reach consensus on at least one article per day, which may be overly ambitious”.

Delegates have also resolved to include consultation with experts as part of the process. This is high time, given that the structures and processes they agree on should be workable for frontline pandemic ‘responders’: scientists studying pathogens, pharmaceutical companies making medicines, health workers and government officials trying to contain outbreaks. But it will mean more time is needed.

New co-chair Anne-Claire Amprou also told delegates on Wednesday that they would need to decide by 11 November – not 15th, as assumed the previous day – if there was sufficient agreement to call a World Health Assembly (HWA) special session in December to adopt a pandemic agreement...

This prompted the European Union’s Americo Zampetti to comment that such sessions should not simply serve as information giving but also solicit the inputs and opinions of the stakeholders, which range from patient advocacy organisations to pharmacuetical companies...

read more here